Browsing Enfermidades endocrinas, nutricionais e metabólicas by Subject "Acromegaly"
Now showing items 1-5 of 5
-
Cost-effectiveness analysis of preoperative treatment of acromegaly with somatostatin analogue on surgical outcome
(Elsevier, 2015-08-20)[Abstract] Context. There is no uniform standard of care for acromegaly. Due to the high costs involved, steps must be taken to ensure the cost-effective delivery of treatment. Objective. Taking the results of an earlier ... -
Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly
(Springer, 2020-07-28)[Abstract] Purpose. Recent data indicate that extended dosing intervals (EDIs) with lanreotide autogel 120 mg are effective and well-received among patients with acromegaly who have achieved biochemical control with monthly ... -
Factors associated with therapeutic response in acromegaly diagnosed in the elderly in Spain
(Frontiers, 2022-09-16)[Abstract] Context: Some reports suggest that acromegaly in elderly patients has a more benign clinical behavior and could have a better response to first-generation long-acting somatostatin receptor ligands (SRL). However, ... -
Practical guidelines for diagnosis and treatment of acromegaly
(Elsevier, 2013-10)[Abstract] Acromegaly and gigantism are due to excess GH secretion, usually by a pituitary adenoma. It is an uncommon disease. Diagnosis is made by showing elevated GH and IGF-I levels in patients with a clinical picture ... -
Treatment adherence to pegvisomant in patients with acromegaly in Spain: PEGASO study
(Springer, 2019-02-13)[Abstract] PURPOSE: The burden of chronic daily subcutaneous administration of pegvisomant on adherence has not been previously studied. This study was aimed to determine the adherence to pegvisomant treatment in acromegaly ...